Janney Montgomery Scott LLC bought a new stake in shares of VanEck Biotech ETF (NASDAQ:BBH – Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 3,065 shares of the company’s stock, valued at approximately $481,000. Janney Montgomery Scott LLC owned about 0.12% of VanEck Biotech ETF as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of the stock. Truist Financial Corp boosted its holdings in shares of VanEck Biotech ETF by 3.8% during the second quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock worth $455,000 after purchasing an additional 100 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in shares of VanEck Biotech ETF by 10,376,390.9% during the third quarter. International Assets Investment Management LLC now owns 1,141,414 shares of the company’s stock worth $202,475,000 after purchasing an additional 1,141,403 shares during the last quarter. Tyler Stone Wealth Management boosted its holdings in shares of VanEck Biotech ETF by 79.5% during the third quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock worth $261,000 after purchasing an additional 652 shares during the last quarter. Coastline Trust Co acquired a new stake in shares of VanEck Biotech ETF during the third quarter worth $59,000. Finally, Truvestments Capital LLC acquired a new stake in shares of VanEck Biotech ETF during the third quarter worth $44,000. Institutional investors and hedge funds own 32.05% of the company’s stock.
VanEck Biotech ETF Stock Performance
BBH stock opened at $163.01 on Monday. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64. The stock’s fifty day simple moving average is $161.93 and its 200-day simple moving average is $170.46.
VanEck Biotech ETF Dividend Announcement
VanEck Biotech ETF Profile
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
See Also
- Five stocks we like better than VanEck Biotech ETF
- Differences Between Momentum Investing and Long Term Investing
- 3 Volatility ETFs to Help You Profit from Market Chaos
- The How and Why of Investing in Gold Stocks
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- Manufacturing Stocks Investing
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.